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Introduction
Mitofusin-2 (MFN2) is a mitochondrial GTPase that plays a pivotal 
role in mitochondrial dynamics, including regulation of mitochon-
drial fusion, transport, mitophagy, mtDNA stability, and mito-
chondria-ER interactions (1–5). Given the high-energy demand 
of neurons coupled with their unique cellular architecture (axons, 
dendrites), proper mitochondrial dynamics are required to provide 
energy when and where it is needed (6, 7). Disruption of mitochon-
drial dynamics has been linked to a diverse spectrum of neuro-
logical conditions, including Parkinson’s disease and Alzheimer’s 
disease (7, 8). In some of these cases, alterations in MFN2 function 
and mitochondrial dynamics may play a role in disease pathogen-
esis. For example, in Parkinson’s disease, MFN2 plays a key role in 
PINK1-Parkin–mediated mitophagy (5, 9) and Mfn2 knockout in 
dopaminergic neurons impairs Parkin localization to mitochondria, 
leading to severe axonal loss (10). In Alzheimer’s disease, MFN2 
protein levels are decreased in both patient brain tissue and trans-
genic mouse models, and amyloid-β–mediated disruption of mito-
chondrial dynamics may contribute to the toxicity of amyloid-β (11, 
12). However, while MFN2 function has been implicated in a variety 
of diseases, MFN2 mutations are only directly responsible for Char-
cot-Marie-Tooth disease type 2A (CMT2A) (13).
CMT is one of the most common inherited neurological dis-
orders, and MFN2 mutations are the most frequently identified 
cause of axonal CMT (CMT type 2). Most cases are de novo domi-
nant or show dominant inheritance, although recessive cases have 
also been reported (13, 14). The typical clinical features of CMT2A 
include early onset and progressive distal weakness, muscle atro-
phy, and sensory loss from degeneration of long peripheral axons 
(15). However, CMT2A represents a broader spectrum of neuro-
logic disease, including optic atrophy (16), spastic paraparesis (17), 
hearing loss (18), developmental delay (19), and brain white matter 
changes (18). This indicates that, while long peripheral axons are 
most sensitive to MFN2 mutations, CMT2A is actually a broader 
disorder of primarily the central and peripheral nervous systems 
that can rarely also involve muscle or fat tissue (20, 21).
As MFN2 is ubiquitously expressed and loss of function is 
detrimental to many tissues (1, 4, 10, 22–25), it remains unclear 
what causes MFN2 mutations to preferentially affect the ner-
vous system, although key candidates include the low level of 
MFN1 expression relative to other tissues and the unique energy 
demands of axons, which require proper mitochondrial transport 
and localization (6, 7, 26). MFN1 can compensate for loss of MFN2 
and protect the mitochondrial fusion and transport defects caused 
by MFN2 mutants in vitro (26, 27). However, it has been chal-
lenging to investigate the role of the MFN1/MFN2 ratio in vivo, 
as existing CMT2A transgenic mouse models have either a static 
congenital phenotype (28) or a mild late-onset phenotype (29–31), 
with none recapitulating the severity or broader spectrum of neu-
rological damage observed in CMT2A patients.
To better understand the role of MFN2 mutation in vivo, 
we generated transgenic mice expressing either WT or point 
mutant (MFN2R94Q ) under the neuronal-specific Thy1.2 pro-
moter. Thy1.2-MFN2R94Q transgenic mice recapitulated a range 
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Figure 1. Impaired growth rate, sensorimotor function, grip strength, and vision in Thy1.2-MFN2R94Q transgenic mice. (A) Schematic of the 
Thy1.2-MFN2R94Q transgenic construct. The expression of human MFN2R94Q or control MFN2WT (N terminus tagged with Flag) was driven by the 
neuron- specific mouse Thy1.2 promoter. (B) Representative image of a nontransgenic (nTg) mouse, a Thy1.2-MFN2WT mouse, and a Thy1.2-MFN2R94Q  
mouse (5 months old). (C) Immunoblot of Flag-MFN2WT or Flag-MFN2R94Q transgene expression (14-month-old mice). Red arrow, Flag-MFN2; black 
arrow, endogenous mouse Mfn2. Expression levels of MFN2WT or MFN2R94Q transgenes were identical and slightly below endogenous Mfn2 levels. 
n = 3 mice/genotype. (D) Immunostaining of Flag-MFN2WT or Flag-MFN2R94Q protein expression and localization. Mouse cortex or spinal cord 
(5-month-old mice). Anti-Flag (red) and DAPI (blue). Scale bars: 50 μM. Punctate mitochondrial staining was observed in both transgenic lines, 
but only MFN2R94Q mice showed mitochondrial accumulations in neuronal cytoplasm and proximal axons. n = 3 mice/genotype. (E) Body weight. 
Data are represented as mean ± SEM. n = 6–52 per genotype per time point. Student’s 2-tailed t test (nTg vs. MFN2R94Q). *P < 0.05. (F) Survival 
curve. nTg (n = 59), MFN2WT (n = 29), MFN2R94Q (n = 124). log-rank test with Bonferroni’s correction. nTg vs. MFN2WT, P > 0.05, not significant. nTg 
vs. MFN2R94Q, P < 0.01. MFN2WT vs. MFN2R94Q, P < 0.05. (G) Open-field test (total activity) and (H) open-field test (rearing). Total activity was not 
significantly different between groups. nTg (n = 5), MFN2WT (n = 5), MFN2R94Q (n = 6) (3-month-old mice). (I) Rotarod testing. nTg (n = 5), MFN2WT 
(n = 5), MFN2R94Q (n = 6). (J) Grip-strength testing (forelimbs). nTg (n = 8–11), MFN2WT (n = 5), MFN2R94Q (n = 6). (K) Visual acuity measured by OKR. 
nTg (n = 6), MFN2WT (n = 3), MFN2R94Q (n = 7). In G-K, data are represented as mean ± SEM. Two-way ANOVA with Tukey’s test was used for multiple 
comparison. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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mutants (28, 32). The mutant MFN2R94Q-induced mitochondrial 
accumulations were not due to MFN overexpression, as they were 
not seen in Thy1.2-MFN2WT transgenic mice.
Reduced growth rate, sensorimotor deficits, and vision loss in 
Thy1.2-MFN2R94Q mice. Both MFN2WT and MFN2R94Q mice were 
born at normal Mendelian ratios. While MFN2WT mice were indis-
tinguishable from nontransgenic mice, MFN2R94Q mice showed 
stunted growth (Figure 1, B and E) and died prematurely from 
failure to thrive (25% died by 15 months of age; Figure 1F). By 
3 months of age, MFN2R94Q mice showed a wobbling gait defect 
and occasionally dragged their hind limbs (Supplemental Vid-
eo 1). By 10 months, MFN2R94Q mice had severe uncoordinated 
movements and hind limb paw clasping (Supplemental Figure 3), 
a neurologic finding commonly seen in mouse models of neuro-
degeneration (36).
No change in total activity was present on open-field testing; 
however, rearing activity (standing up on the side of the cage) was 
reduced in MFN2R94Q mice (Figure 1, G and H). On rotarod testing, 
MFN2R94Q mice fell off significantly earlier than either MFN2WT 
or nontransgenic mice and did not improve over time (Figure 1I). 
MFN2R94Q mice also showed weaker grip strength than MFN2WT or 
nontransgenic control mice (Figure 1J). Given that some CMT2A 
patients have optic atrophy and vision loss, we examined response 
to visual stimulation on optokinetic response (OKR) testing and 
found that MFN2R94Q mice also had severe vision loss (Figure 1K). 
While MFN2R94Q mice declined in terms of overt coordination and 
clasping, most of these phenotypes were static and early onset. The 
early onset and sensorimotor deficits with vision loss in MFN2R94Q 
mice are consistent with the broader spectrum of neurologic dys-
function seen in the more severe CMT2A patients, including those 
carrying the R94Q mutation who typically have onset in the first 
decade of life.
Axon atrophy and degeneration without neuronal cell body loss in 
MFN2R94Q mice. CMT2A patients have a spectrum of neurologic dys-
function, including optic atrophy (16), spinal cord involvement with 
spastic paraparesis (17), and brain involvement with developmental 
delay (18, 19). We therefore examined MFN2R94Q mice broadly for 
neuronal and axonal pathology in the central and peripheral nervous 
system. At 5 months of age, we observed diffuse axon degeneration 
on Fluoro-Jade staining in white matter tracts of the brain, including 
pyramidal tracts of the medulla and the lumbar spinal cord (Figure 
2A). Surprisingly, in the distal tibial nerve, which typically shows 
severe axon loss in CMT2A patients, axons were smaller in caliber, 
but were normal in number, without degenerating profiles such as 
those seen in the spinal cord or brain (Figure 2, B and C). Similar axo-
nal atrophy without degeneration has been observed in other mouse 
models of axonal CMT (29, 37, 38), possibly due to shorter length, spe-
cies differences, or lower promoter expression in peripheral neurons. 
In whole mounted retinas, neurofilament staining showed beaded, 
swollen, and degenerating axons with atrophic retinal ganglion cells 
(RGCs) in MFN2R94Q mice (Figure 2D). In optic nerves, SMI32 stain-
ing showed significant neurofilament loss and axonal spheroids in 
MFN2R94Q mice (Figure 2E and Supplemental Figure 4A), presum-
ably explaining the vision loss in these animals. Interestingly, axon 
degeneration occurred in the absence of cell body loss throughout the 
nervous system, as no quantitative neuronal loss was observed in the 
retina, brain, or spinal cord, including motor cortex, sensory cortex, 
of neurologic features seen in CMT2A patients, including 
severe early onset sensorimotor deficits, vision loss, altered 
mitochondrial dynamics, and widespread axonal degeneration. 
Increased expression of MFN1 in the nervous system rescued 
MFN2R94Q mutant phenotypes, demonstrating that the balance 
of MFN isoforms is likely the key contributor to nervous system 
selectivity in CMT2A and providing proof of concept in vivo 
that augmenting MFN1 levels is a potential therapeutic strategy 
for the disease.
Results
Generation of transgenic mice expressing human MFN2WT or MFN2R94Q 
in neurons. We generated transgenic mice expressing Flag-tagged 
human MFN2 WT (MFN2WT) protein or mutant (MFN2R94Q ) under 
the Thy1.2 promoter to drive neuronal expression (Figure 1, A and 
B). We chose this promoter because it drives expression postna-
tally in most neurons, including projection neurons of the brain 
and spinal cord, which are most severely affected in CMT2A and 
show cell-autonomous defects from mutant MFN2 expression in 
vitro (32). We selected the R94Q variant, as dominant point muta-
tions in this and neighboring residues in the GTPase domain have 
been reported across numerous ethnic backgrounds with a con-
sistently severe phenotype with onset in the first decade that may 
include optic atrophy, spasticity, developmental delay, and brain 
white matter abnormalities (13, 17, 33–35) and as previous in vitro 
studies demonstrated a dominant negative effect on mitochon-
drial fusion and transport (3, 26, 27, 32). We focused our analysis 
on 2 transgenic lines that showed comparable expression of either 
MFN2WT (WT-47 line) or MFN2R94Q (R94Q-44 line). Because the 
Thy1.2-MFN2R94Q transgene was integrated into the Y chromo-
some in the R94Q-44 line, only male mice were analyzed for both 
lines. A second mutant transgenic line (R94Q-62) was also gen-
erated with a similar phenotype in both males and females (Sup-
plemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI124194DS1), but because 
it was more severe and difficult to propagate, we focused analysis 
on the R94Q-44 line.
Western blot using an antibody to Flag showed specific 
expression of transgenic MFN2WT or MFN2R94Q protein at the 
expected size of approximately 84 kDa (Figure 1C), with expres-
sion of the transgene slightly lower than that of endogenous 
mouse Mfn2 (Figure 1C). Immunofluorescence staining with 
anti-Flag antibody confirmed punctate cytoplasmic expres-
sion of exogenous MFN2WT and MFN2R94Q that colocalized with 
COXIV, consistent with mitochondrial localization in neurons 
in brain and spinal cord (Figure 1D and Supplemental Figure 2). 
Occasionally, the center of the densest mitochondrial clusters 
showed diminished COXIV staining, which may represent partial 
degradation of mitochondrial components at the center of the 
cluster (Supplemental Figure 2). Of note, large accumulations of 
mitochondria were observed in neuronal cell bodies and proximal 
axons in cortex and spinal cord of Thy1.2-MFN2R94Q mice; these 
were not present in Thy1.2-MFN2WT mice (Figure 1D and Sup-
plemental Figure 2). Similar mitochondrial clustering was also 
observed in the more severe R94Q-62 line (Supplemental Figure 
1). These mitochondrial accumulations were reminiscent of those 
previously observed in cultured (DRG) neurons expressing MFN2 
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Figure 2. Widespread axon degeneration and gliosis without neuronal cell loss in MFN2R94Q mice. (A) Degenerating axons labeled with Fluoro-Jade 
staining in the brain pyramidal tracts of the medulla and the spinal cord of MFN2R94Q mice (5 months old). Scale bar: 50 μM. Graph represents the 
quantification of Fluoro-Jade–positive signal as pixel2 per mm2 ROI subtracted from background. Data are represented as mean ± SEM. n = 3 mice/
genotype. Student’s t test, 2-tailed for pyramidal track and 1-tailed for spinal cord. *P < 0.05. (B) Toluidine blue–stained plastic sections of spinal 
cord and tibial nerves from 14-month-old nTg or MFN2WT and MFN2R94Q mice. Scale bars: 10 μM (spinal cord); 50 μM (tibial nerve). Arrows indicate 
degenerating axons in the spinal cord. Tibial nerve showed axonal atrophy without axonal loss. n = 3 mice/genotype. (C) Size frequency histogram 
of tibial nerve axons (n = 3 mice/group) showing axonal atrophy in MFN2R94Q mice (Kolmogorov-Smirnov test, P < 0.0001). (D) RGC axons stained 
with neurofilament antibody (RT97) in retinal whole-mount preparations. Scale bars: 50 μM. Arrowheads indicate beaded axons, and arrows 
indicate atrophic RGCs, seen only in MFN2R94Q mice. n = 2 mice/genotype. (E) Neurofilament in cross sections of optic nerve stained with SMI32 
antibody. Scale bar: 50 μM. Axonal spheroids (white arrowheads) were present in the optic nerves of MFN2R94Q mouse (3 months old). Graph rep-
resents the quantification of axonal spheroids. Data are represented as mean ± SEM. n = 4 /genotype. Student’s t test, 2-tailed. ****P < 0.0001. (F) 
Astrocyte activation was present in regions of MFN2R94Q mouse brains (brain stem shown here) in areas of projection neurons that contained mito-
chondrial aggregates (5-month-old mice). GFAP (green); Flag (red); DAPI (blue). Scale bar: 50 μM. n = 3 mice/genotype. (G) Microgliosis in regions of 
MFN2R94Q mouse brains (cortex shown here) (5-month-old mice). Iba1 (green); Flag (red); DAPI (blue). Scale bar: 100 μM. n = 3 mice/genotype.
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and ventral horn (Supplemental Figure 4, B and C, and Supplemental 
Figure 5A). While no neuronal degeneration was observed, reactive 
astro- and microgliosis (enhanced Gfap and Iba1 immunoreactivity) 
were observed adjacent to projection neurons in cortical layer 5 
and brain stem motor nuclei (Figure 2, F and G, and Supplemental 
Figure 5, B and C). Costaining with Flag to label mutant MFN2R94Q- 
containing mitochondria showed that gliosis was most pronounced 
adjacent to neurons with cytoplasmic accumulations of mitochon-
dria (Figure 2F). These results indicate that MFN2R94Q expression 
produced widespread axon degeneration in the brain and spinal cord, 
particularly in regions containing long projection neurons. While 
neuronal cell bodies showed cytoplasmic mitochondrial accumula-
tions and adjacent gliosis, no cell body loss was observed.
Mitochondrial clustering and morphology abnormalities induced by 
MFN2R94Q. To better visualize mitochondrial morphology and accu-
mulations, we crossed MFN2R94Q mice to transgenic mice with cyan 
fluorescent protein–labeled (CFP-labeled) mitochondria (39). By 8 
months, accumulations of CFP-labeled mitochondria were observed 
in hippocampus, cortex, thalamus, cerebellum, brain stem, and spi-
nal cord in MFN2R94Q:CFP-COX8A double-transgenic mice (Figure 
3A and Supplemental Figure 6A); these were similar to what was 
seen with anti-Flag antibody (Figure 1D). Despite the accumulation 
of mitochondria in spinal motor neurons, mitochondria were pres-
ent in distal axons and at neuromuscular junctions (NMJs), although 
they were frequently clumped or clustered (Figure 3B); this is remi-
niscent of findings seen in nerve biopsy samples from patients with 
CMT2A (40, 41). While NMJs showed abnormal shape in the MFN-
2R94Q:CFP-COX8A double-transgenic mice, NMJ occupancy was 
normal at 8 months of age (Figure 3B). Neuronal cytoplasmic mito-
chondrial accumulations were positive for both p62 and ubiquitin 
(Figure 3C and Supplemental Figure 6, B–E), indicating they were 
marked for degradation by mitophagy. While early studies report-
ed mitochondrial clustering from extremely high-level WT MFN2 
overexpression in tissue culture (42), no mitochondrial clustering 
was observed in MFN2WT transgenic mice despite similar levels of 
expression, indicating this was a mutant-specific effect (Figure 3C).
Dominant negative disruption of mitochondrial fusion, but not mito-
phagy, by MFN2R94Q. Accumulations of fragmented mitochondria in 
cell bodies and axons from CMT2A-related MFN2 mutants were 
previously demonstrated in cultured neurons, together with disrup-
tion of mitochondrial fusion and transport induced by MFN2R94Q 
(3, 26, 32). However, given subsequent studies defining a role of 
MFN2 in mitophagy (5, 9), we investigated whether mutant MFN2R94Q 
could disrupt mitophagy directly, leading to accumulation of mito-
chondria in the cell body that could not be degraded. Therefore, 
we examined mouse embryonic fibroblasts (MEFs) expressing 
MFN2WT or MFN2R94Q via lentiviruses. The mitochondrial aspect 
ratio (length/width), a measure of mitochondrial fusion (43), was 
significantly decreased in MEFs expressing MFN2R94Q , but increased 
in MEFs expressing MFN2WT, in comparison with control MEFs 
(Figure 3, D and E). Additionally, a significant (P < 0.0001) increase 
in depolarized mitochondria was observed in MEFs expressing 
MFN2R94Q compared with control MEFs or those expressing 
MFN2WT (Figure 3, D and E). These data indicate that MFN2R94Q 
suppresses mitochondrial fusion in a dominant negative manner 
and that this suppression is accompanied by disruption of mito-
chondrial membrane potential. To assess mitophagy directly, we 
treated MEFs with trifluoromethoxy carbonyl cyanide phenylhy-
drazone (FCCP), which uncouples oxidative phosphorylation and 
ATP production and leads to Parkin-dependent mitophagy (5). 
Parkin translocation from the cytosol to mitochondria was not dif-
ferent between MEFs expressing MFN2R94Q and controls (Figure 
3, F and G), indicating MFN2R94Q is recognized normally by the 
Pink1/Parkin mitophagy pathway. Additionally, mitochondria- 
lysosome colocalization was normal in MFN2R94Q-expressing MEFs 
and increased similarly after mitophagy induction with FCCP 
treatment (Figure 3, H and I). These data indicate that mutant 
MFN2R94Q does not disrupt Parkin-mediated mitophagy and that 
the mitochondrial accumulations observed in MFN2R94Q mice are 
not due to a direct block in mitochondrial degradation.
Conformation-altering peptides and MFN1 complementation 
for MFN2R94Q-induced defects. The MFN2R94Q mutation lies adja-
cent to the GTPase domain, which is a hot spot for CMT2A muta-
tions (44). While there are several models of MFN2 structure and 
conformation during mitochondrial fusion, all require GTPase 
function for fusion of the outer mitochondrial membrane (43, 
45–48). In the most well-studied model, initial tethering involves 
C-terminal heptad-repeat 2 (HR2) domains in trans, with subse-
quent GTPase domain–mediated GTP hydrolysis (43, 45). There-
fore, MFN2 GTPase mutants such as MFN2R94Q are competent 
for initial tethering with MFN1 or MFN2 on adjacent mitochon-
dria, but are unable to complete fusion (Figure 4A).
To test this model and investigate potential therapeutic strategies 
for CMT2A, we first examined the effect of a recently described pep-
tide (TAT-MP1Gly) that allosterically enhances mitochondrial fusion 
through altering C-terminal heptad repeat (HR1-HR2) interactions 
Figure 3. Dominant negative disruption of mitochondrial fusion, 
but not mitophagy, by MFN2R94Q. (A) Cytoplasmic accumulations of 
mitochondria in the hippocampus of MFN2R94Q:CFP-COX8A mutant mice, 
not seen in CFP-COX8A control mice (7-month-old mice). Scale bar: 100 
μM. n = 2 mice/genotype. (B) Mitochondrial clustering was also seen in 
distal peripheral nerve and NMJ of MFN2R94Q:CFP-COX8A mice (quadri-
ceps muscle shown). NMJ was labeled with α-bungarotoxin (BTX, red). 
Arrowheads indicate mitochondrial clusters in distal axons (7-month-old 
mice). Scale bar: 50 μM. n = 2 mice/genotype. (C) Mitochondrial accumu-
lations in MFN2R94Q mice were colocalized with p62 protein, indicating 
they were marked for mitophagy. Anti-Flag staining labels transgen-
ic MFN2. DAPI labels nuclei (5-month-old mice). Scale bars: 50 μM. 
Numbers of p62 aggregates per ROI (0.01 mm2) are quantified. Data are 
represented as mean ± SEM. n = 3 mice/genotype. Student’s 2-tailed t 
test, **P < 0.01. (D) Effects of MFN2R94Q on mitochondrial fusion, mem-
brane potential, and mitophagy in MEFs. MEFs were infected with β-gal 
(control), MFN2WT, or MFN2R94Q lentivirus. Depolarization was induced by 
treating MEFs with FCCP (10 μM) for 1 hour. Mitochondria were labeled 
with MitoTracker (green) and TMRE (red). Scale bar: 10 μM. (E) Quan-
tification of D. Mitochondrial fusion at the basal level is presented as 
mitochondrial aspect ratio measurement (mitochondrial length/width; 
n = 9 repeat experiments). Initiation of mitophagy is presented as mito-
chondrial depolarization ratio (green/green+yellow mitochondria; n = 3). 
(F) Parkin localization. MEFs were infected with adenovirus expressing 
RFP-parkin. Scale bars: 10 μM. (G) Quantification of parkin localization 
in F (n = 3 repeat experiments). (H) Colocalization of mitochondria 
and lysosome. Mitochondria were labeled with MitoTracker Green, and 
lysosomes were labeled with LysoTracker Red. Scale bars: 10 μM. (I) 
Quantification of mitochondria and lysosome colocalization in H (n = 3 
repeat experiments). In E, G, and I, data are represented as mean ± SEM. 
One-way ANOVA with Tukey’s test. **P < 0.01; ****P < 0.0001.
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and promoting a “tethering permissive” state (43). We observed that 
the TAT-MP1Gly peptide partially rescued the fusion defect caused by 
MFN2R94Q in MEFs lacking endogenous mouse Mfn2 (but retaining 
Mfn1), but could not rescue fusion in double-knockout MEFs (lacking 
both Mfn1 and Mfn2) (Figure 4, B and C). This supports that MFN2R94Q 
by itself is fusion incompetent and that the TAT-MP1Gly peptide 
requires at least one functioning Mfn isoform (in this case Mfn1) to 
promote fusion as well as that presumably in MEFs, the peptide is 
Figure 4. Model of dominant negative function by MFN2R94Q mutation and effect of conformation-altering peptides and MFN1 complementation. 
(A) Model of MFN2R94Q mutant dominant negative function and effect of allosteric peptide TAT-MP1Gly. Alteration of GTPase activity does not affect 
initial mitochondrial tethering (mediated by HR2 domain), but leads to inability to fuse after tethering. TAT-MP1Gly peptide drives the tethering 
permissive state in this model by blocking HR1-HR2 interaction. (B) Mitochondrial fusion defects caused by MFN2R94Q are only rescued by TAT-MP1Gly 
in the presence of Mfn1 in MEFs. MEFs lacking either Mfn2 alone or both Mfn1 and Mfn2 were infected with MFN2R94Q lentivirus and imaged with 
MitoTracker Green and TMRE to label mitochondria. Scale bar: 10 μM. (C) Quantification of B. Mitochondrial fusion is presented as mitochondrial aspect 
ratio measurement (mitochondrial length/width). TAT-MP1Gly only improved mitochondrial fusion in the presence of functioning Mfn1, but not in cells 
lacking all functional Mfns. Data are represented as mean ± SEM (n = 3 repeat experiments). Student’s 2-tailed t test. *P < 0.05. (D) MFN2R94Q-induced 
mitochondrial aggregation was enhanced by TAT-MP1Gly peptide in a neuronal cell line (SH-SY5Y cells) and rescued by increased MFN1 expression. MFNs 
were expressed by lentivirus, with mito-RFP to visualize mitochondria. Original magnification, ×20 (upper panels). Inset boxes are shown at higher 
magnification below (×3 magnification). Scale bar: 100 μM. Representative of 3 repeat experiments. (E) Quantification of D. Data are represented as 
mean ± SEM (n = 5). One-way ANOVA with Tukey’s test was used for multiple comparisons. **P < 0.01; ****P < 0.0001.
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Figure 5. Phenotypic rescue of MFN2R94Q mice by augmenting MFN1 expression in the nervous system. (A) Schematic of the Prp-MFN1 transgene. 
The expression of human MFN1 (N terminus tagged with Flag) in brain and spinal cord is driven by the murine Prp gene promoter. Prp-MFN1 trans-
genic mice were crossed with Thy1.2-MFN2R94Q transgenic mice to generate Thy1.2-MFN2R94Q:Prp-MFN1 double-transgenic mice. (B) Representative 
image of a 20-week-old MFN2R94Q:MFN1 double-transgenic mouse compared with a MFN2R94Q mutant mouse and an nTg control. (C) MFN1 and/
or MFN2R94Q transgene expression detected by immunoblotting. Lysates of 14-month-old mouse brain and spinal cord. Expression levels of the 2 
MFN transgenes were comparable. Note low level of endogenous Mfn1 expression in the mouse brain and spinal cord. n = 3 mice/genotype. (D) Flag 
immunostaining of MFN1 transgenic protein in 7-week-old mouse spinal cord showing punctate cytoplasmic staining consistent with mitochondria. 
DAPI stains nuclei. Scale bar: 100 μM. n = 3 mice/genotype. (E) Body weight. Data are represented as mean ± SEM. nTg (n = 8–32 per time point), 
MFN2R94Q (n = 24–63 per time point), and MFN2R94Q:MFN1 (n = 17–31 per time point). Two-way ANOVA with Tukey’s multiple comparisons test. *P < 
0.05; ****P < 0.0001. MFN2R94Q vs. MFN2R94Q:MFN1 (asterisks in black). nTg vs. MFN2R94Q:MFN1 (asterisks in gray). (F) Survival curve. nTg (n = 8–32 
per time point), MFN2R94Q (n = 24–63 per time point), and MFN2R94Q:MFN1 (n = 17–31 per time point). log-rank test with Bonferroni’s correction. 
nTg vs. MFN2R94Q, P < 0.01; MFN2R94Q vs. MFN2R94Q:MFN1, P < 0.01. nTg vs. MFN2R94Q:MFN1, P > 0.05 (not significant). (G) Open-field test (rearing). 
nTg (n = 5), MFN2R94Q (n = 5), and MFN2R94Q:MFN1 (n = 10). (H) Rotarod testing. nTg (n = 3–5), MFN2R94Q (n = 3–5), and MFN2R94Q:MFN1 (n = 3–10). (I) 
Grip-strength testing (all paws). nTg (n = 3–5), MFN2R94Q (n = 3–5), and MFN2R94Q:MFN1 (n = 3–10). (J) Visual acuity measured by OKR. nTg (n = 6), 
MFN2R94Q (n = 7), and MFN2R94Q:MFN1 (n = 4). In G–J, data are represented as mean ± SEM. Two-way ANOVA with Tukey’s test was used for multiple 
comparison. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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MFN2R94Q:MFN1:CFP-COX8A mice showed rescue of CFP-labeled 
mitochondrial clustering in hippocampus (Figure 6A). Immuno-
fluorescence staining with anti-Flag and anti-p62 antibodies con-
firmed that MFN1 augmentation completely rescued the mitochon-
drial clustering caused by MFN2R94Q (Figure 6B and Supplemental 
Figure 7B). Fluoro- Jade staining demonstrated complete rescue of 
degenerating axons in the spinal cords of MFN2R94Q:MFN1 mice in 
comparison with MFN2R94Q mice (Figure 6C and Supplemental Fig-
ure 7C). The number of axonal neurofilament spheroids was sig-
nificantly rescued in MFN2R94Q:MFN1 mice when compared with 
MFN2R94Q mice (Figure 6D and Supplemental Figure 7D). Finally, 
Gfap and Iba1 immunofluorescence staining were normalized in 
MFN2R94Q:MFN1 mice (Figure 6, E and F, and Supplemental Figure 
7, E and F), consistent with rescue of the microglial and astrocytic 
reactions seen in MFN2R94Q mice.
To analyze transcriptome alterations in MFN2R94Q mice, we 
performed RNA-Seq on the lumbar spinal cords of nontransgenic 
MFN2R94Q and MFN2R94Q:MFN1 animals. Principal component 
analysis (PCA) showed that the first principal component (PC1) 
separated the 3 genotypes, with nontransgenic and MFN2R94Q: 
MFN1 mice clustering more closely together and MFN2R94Q clus-
tering separately (Figure 6G). To define the pathways that drove 
this difference, we performed Gene Set Enrichment Analysis 
(GSEA) on the gene loadings ranked by the most positive to the 
most negative contributions to PC1 and found that oxidative 
phosphorylation and respiration electron transport were the path-
ways most significantly downregulated in PC1, indicating these 
drove the difference between the genotypes, and were rescued 
by MFN1 overexpression (Table 1). Overall, these data provide 
strong evidence that the ratio of MFN1 to MFN2 is a key deter-
minant of the sensitivity of the nervous system to the dominant 
negative effects of mutant MFN2 expression and support the idea 
that elevating MFN1 levels to restore the MFN1/MFN2 balance is 
a viable therapeutic strategy for CMT2A (Figure 6H).
Finally, to further characterize whether MFN2R94Q functions as a 
dominant negative, we first examined whether MFN2WT could also 
rescue the toxic effects of the mutant protein. As with MFN1 (Figure 
4D), increased expression of MFN2WT using lentivirus decreased the 
amount of mitochondrial aggregates induced by mutant MFN2R94Q in 
SH-SY5Y cells in culture (Supplemental Figure 8A). To further deter-
mine whether increasing MFN2WT could rescue the phenotype of 
MFN2R94Q mice, we crossed the MFN2R94Q to the MFN2WT transgenic 
mice. We observed that MFN2R94Q:MFN2WT double-transgenic mice 
showed restored weight gain (Supplemental Figure 8B) and that their 
behavior appeared overtly normal and indistinguishable from that 
of MFN2R94Q:MFN1 mice. As in SH-SY5Y cells, hippocampal mito-
chondrial aggregation was rescued in the MFN2R94Q:MFN2WT double- 
transgenic mice (Supplemental Figure 8C). Finally, we observed that 
increasing MFN2WT levels was able to rescue the axonal degeneration 
seen in the pyramidal tract of MFN2R94Q mice (Supplemental Figure 
8D). These data strongly support that MFN2R94Q mutant acts by a 
dominant negative mechanism that can be rescued by increasing the 
number of fusion-competent MFN1 or MFN2 molecules.
Discussion
In this study, we demonstrated that mice with transgenic expression 
of CMT2A-associated mutant MFN2R94Q (but not WT) developed 
rescuing fusion by promoting Mfn1:Mfn1-mediated fusion events. 
Interestingly, lentiviral expression of MFN2R94Q (but not MFN2WT) 
in SH-SY5Y neuroblastoma cells promoted mitochondrial clustering 
similar to that seen in the MFN2R94Q mice, and clustering was exac-
erbated by the TAT-MP1Gly peptide (Figure 4, D and E). This sug-
gests that, because of the lower levels of endogenous MFN1 in this 
neuronal cell line, the further promotion of an HR1-HR2 tethering 
permissive conformation of MFN2R94Q enhanced the frequency of 
failed fusion events and mitochondrial clustering. In keeping with 
the idea that the MFN1/MFN2 ratio is the key determinant of sensi-
tivity to the MFN2R94Q mutant, the mitochondrial aggregation effect 
of MFN2R94Q expression in SH-SY5Y cells was significantly rescued 
by increasing expression of MFN1 (Figure 4, D and E).
In summary, these data support the idea that MFN2R94Q is 
fusion incompetent and can suppress mitochondrial fusion in a 
dominant negative manner depending on the level of available 
fusion-competent MFN1 and MFN2 molecules in the cell. They 
further support the concept that the low levels of MFN1 in the 
nervous system potentially underlie the selective vulnerability of 
neurons in CMT2A (27).
Phenotypic rescue of MFN2R94Q mice by augmenting MFN1 expres-
sion in the nervous system. To examine whether altering the balance 
of MFN1 and MFN2 can mitigate the toxic effects of MFN2R94Q , 
we generated mice expressing Flag-tagged human MFN1 under 
the mouse prion protein (PrP) promoter to drive expression in the 
nervous system (Figure 5, A and B). Western blot confirmed the 
expression of Flag-tagged MFN1 in both brain and spinal cord at 
levels slightly lower than Thy1.2-driven MFN2R94Q (Figure 5C). 
As noted before, endogenous Mfn1 protein was nearly undetect-
able in the nervous system of nontransgenic animals (Figure 5C). 
Despite the high level of Flag-MFN1 expression over endogenous 
Mfn1, normal punctate mitochondrial staining was observed in 
cell bodies (Figure 5D) and animals were phenotypically and his-
tologically normal throughout their life spans.
We then crossed Prp-MFN1 mice with Thy1.2-MFN2R94Q mice 
to generate the double-transgenic (MFN2R94Q:MFN1) mice. Expres-
sion of MFN1 in the nervous system rescued the stunted growth and 
reduced survival seen in MFN2R94Q mice (Figure 5, E and F). MFN2R94Q: 
MFN1 mice appeared phenotypically normal with a normal gate (Sup-
plemental Video 2) and did not exhibit clasping even at advanced 
ages (Supplemental Figure 7A). In comparison with MFN2R94Q mice, 
MFN2R94Q:MFN1 double-transgenic mice had marked improvement 
in rearing activity in open-field testing, rotarod fall latency, and grip 
strength (Figure 5, G–I). Visual acuity of MFN2R94Q:MFN1 double- 
transgenic mice was restored to the level of nontransgenic mice 
(Figure 5J). In summary, increasing the level of MFN1 in the nervous 
system was well tolerated and provided complete or near-complete 
phenotypic rescue of defects in locomotor activity, sensorimotor coor-
dination, and vision loss in MFN2R94Q mice.
Mitochondrial aggregation, axon degeneration, and transcriptom-
ic signature rescued by MFN1 augmentation. We next determined 
whether increasing MFN1 levels in the nervous system could 
rescue the mitochondrial clustering, axon degeneration, and gli-
osis seen in Thy1.2-MFN2R94Q mice. To examine mitochondrial 
morphology and accumulations, we generated triple-transgenic 
mice carrying MFN2R94Q, MFN1, and CFP-COX8A to fluorescently 
label mitochondria. Compared with MFN2R94Q:CFP-COX8A mice, 
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less common features, including optic atrophy with vision loss, long 
tract spinal cord involvement, and brain involvement (15, 16, 18). 
These data support clinical observations that CMT2A is a broader 
disease of the nervous system, with long peripheral and central 
a widespread axonopathy of the central and peripheral nervous 
systems, with defects in mitochondrial dynamics in neuronal cell 
bodies and axons. The phenotype resembled the severe early onset 
disease seen in most CMT2A patients and included some of the 
Figure 6. Increased expression of MFN1 rescued the mitochondrial accumulation, axon degeneration, gliosis, and transcriptomic changes seen in MFN2R94Q 
mice. (A) Mitochondrial accumulation labeled with CFP-COX8A in vivo (7-month-old mice). Scale bar: 100 μM. n = 2 mice/genotype. The photograph for MFN-
2R94Q:CFP-COX8A is the same as in Figure 3A. (B) Colocalization of clustered mitochondria with p62. Flag-MFN2R94Q (red), p62 (green), DAPI (blue). Scale bar: 50 
μM. n = 3–4 mice/genotype. (C) Degenerating axons stained with Fluoro-Jade in the spinal cord (5-month-old mice). Scale bar: 50 μM. n = 2–3 mice/genotype. 
(D) Neurofilament in cross sections of optic nerve stained with SMI32 antibody. Scale bar: 50 μM (3-month-old mice). n = 3–4 mice/genotype. (E) Astrogliosis 
in brains (brain stem shown here) of 5-month-old mice. Gfap (green), Flag (red), and DAPI (blue). Scale bar: 50 μM. n = 3 mice/genotype. (F) Microglial staining 
in brains (cortex shown here) of 5-month-old mice. Iba1 (green), Flag (red), and DAPI (blue). Scale bar: 100 μM. n = 3 mice/genotype. (G) PCA of RNA-Seq data 
of lumbar spinal cord (10 months old). n = 3–5 mice/genotype. (H) Schematic diagram of a model for MFN1:MFN2 heterotypic interactions in cis in a torus-like 
conformation. The balance of MFN1 and MFN2 on mitochondria in different cell types determines the sensitivity to a dominant negative MFN2 mutant within a 
multimolecular complex (WT MFN shown with circular head, mutant MFN2 as a diamond). Altering the MFN1:MFN2 balance through increasing MFN1 protein in 
neurons restores mitochondrial fusion and other MFN functions despite the continued presence of mutant MFN2R94Q.
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cord of MFN2T105M transgenic mice (31) and neurons cultured from 
MFN2T105M transgenic mice (28). It has also been a consistent fea-
ture in tissue culture models (26, 27, 32). Mitochondrial accumu-
lations in cell bodies were labeled with p62, indicating they were 
marked for degradation via mitophagy (53); however, we did not 
see a difference in Parkin localization or recruitment of mito-
chondria to lysosomes in MEFs expressing MFN2R94Q , suggesting 
that mitochondrial accumulations did not result from a mutant- 
induced block in mitophagy.
What are the causes and consequences of mitochondrial 
aggregation? Our data suggest that effects of mutant MFN2R94Q on 
mitochondrial fusion (27, 32) and engagement with the transport 
apparatus (3, 26, 32) are likely to drive mitochondrial aggregation 
(see Figure 4A). While there are several models of MFN2 structure 
and topology, all involve an initial tethering step, followed by GTP 
hydrolysis as a key step mediating membrane fusion (43, 45–48). The 
most well-studied of these models involves tethering via a C-termi-
nal HR2 domain on adjacent mitochondria (43, 45, 54). In this model, 
MFN exists either in a fusion-nonpermissive conformation through 
HR1-HR2 intramolecular binding or in fusion- permissive conforma-
tion through intermolecular HR2 binding. By this model, GTPase 
domain mutants (such as MFN2R94Q ) are predicted to be competent 
for initial HR2-dependent tethering of adjacent mitochondria, but 
unable to mediate fusion because of GTPase dysfunction. Aggre-
gates of unfused mitochondria would then result from tethered 
mitochondria that were unable to complete fusion or engage trans-
port apparatus. This is supported by the observation that a peptide 
that allosterically modulates HR1-HR2 interactions led to increased 
MFN2-mediated mitochondrial clustering in a neuronal cell line 
(Figure 4D). However, it is important to note that alternative models 
exist whereby MFNs have a different membrane topology (47, 55), 
and other models where initial tethering takes place via the GTPase 
domain rather than the C-terminal HR2 domain (46, 48), so further 
structural biology studies are needed to reconcile these different 
models. Regardless of the precise molecular mechanism, mito-
chondrial aggregation accompanied by decreased mitochondrial 
fusion and axonal transport/localization likely drives axonal degen-
eration in Thy1.2-MFN2R94Q–expressing mice, as numerous prior in 
vitro studies support that degeneration results from local axonal 
energy failure due to abnormal mitochondrial function, interaction 
with other organelles, including ER and lysosomes, and improper 
localization to sites of energy demand (2, 6, 26, 27, 52, 56). Of note, 
a recent study showed that the MFN2R94Q mutant in flies led to sim-
ilar cytoplasmic aggregates of unfused mitochondria and axonal 
pathology, supporting the dominant negative tethering model for the 
action of this and other GTPase domain mutants (57). Interestingly, 
the authors found that 2 other mutants (L76P and R364W) showed 
evidence of enhanced fusion, but surprisingly, still caused mitochon-
drial dysfunction and altered axonal mitochondrial localization. This 
was consistent with earlier findings that the L76P mutant disrupted 
mitochondrial transport (32, 58), but not fusion (27). Further work 
will need to be done to determine whether MFN1 augmentation will 
mitigate the toxic effects of other dominant MFN2 mutants that may 
have different mechanisms of action.
In addition to modeling the toxic effects of mutant MFN2 that 
lead to CMT2A, we provided what we believe is the first in vivo proof 
of concept that restoring MFN1:MFN2 balance by augmenting 
axons most sensitive to the effects of mutant MFN2 (18, 34, 49–51). 
Several previous mouse models of CMT2A from mutant MFN2 
have been generated, but none with the diffuse axonopathy seen in 
Thy1.2-MFN2R94Q mice, particularly in the central nervous system. 
HB9-Mfn2T105M transgenic mice developed hind limb defects, but 
this was distinct from human phenotypes in that it was only seen 
in homozygotes and was congenital and nonprogressive, likely 
because of promoter inactivation after development (28). Mice 
expressing MFN2R94Q under the neuron-specific enolase (NSE) 
promoter showed motor deficits starting at 5 months of age (29, 
52), and mice with MFN2T105M expressed inducibly in the nervous 
system under the Rosa locus developed only mild gait defects (31). 
Finally, MFN2 mutant knockin mice either had no reported phe-
notype (27) or mild late-onset deficits (30). These differences are 
likely due to the use of different promoters and the requirement for 
at least mild overexpression to promote a phenotype. It is notable 
that, while we observed axonal degeneration in the brain and spi-
nal cord of Thy1.2-MFN2R94Q mice, we observed axonal atrophy in 
the distal peripheral nerve without axon loss at a time when the ani-
mals manifested a profound behavioral phenotype. Axonal atrophy 
without degeneration has been observed in a prior CMT2A model 
(29) as well as other mouse models of axonal CMT (37, 38). These 
data suggest that a critical threshold of mutant MFN2 expression is 
required to produce peripheral axonal degeneration in mice, which 
may be due to species-specific factors, such as shorter axon length 
or uncharacterized genetic modifiers. Likewise, they suggest that 
the profound behavioral phenotype in Thy1.2-MFN2R94Q mice is pre-
sumably driven by a combination of vision loss and sensory- motor 
axonal damage in brain and spinal cord. While transgene insertion 
into the Y chromosome was a drawback of the R94Q-44 line, as 
female mice could not be studied, clinical data from humans do 
not support a sex difference in phenotypes, and while the R94Q-62 
line was too severe to maintain, it showed similar pathology in both 
males and females.
The most striking pathologic feature in Thy1.2-MFN2R94Q mice 
was mitochondrial clustering and aggregation in neuronal cell 
bodies and proximal and distal axons. Similar abnormal mito-
chondrial size, morphology, and clustering has been reported in 
the nerve biopsies from CMT2A patients (40, 41). Mutant-specific 
mitochondrial aggregation was also observed in brain and spinal 
Table 1. Pathway analysis of MFN2R94Q mice










GSEA of pathways using ranked gene loadings contributing to PC1 from 
PCA. GO, Gene Ontology. AFDR ≤ 0.05.
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or Flag-MFN2R94Q was cut out from the pEGFP construct and 
subcloned into the Thy1.2 promoter construct (Addgene, cata-
log 20736) to make a Thy1.2-Flag-MFN2WT or Thy1.2-Flag-MF-
N2R94Q construct using the XhoI restriction sites (65). The plas-
mid was linearized with EcoRI and PvuI digestion, gel purified, 
and filter sterilized for pronuclear injection. The MFN2WT or 
MFN2R94Q transgenic mice were created on the C57BL/6J back-
ground (The Jackson Laboratory) with standard pronuclear injec-
tion procedure. Genotyping of founder mice was done using PCR. 
Primers were as follows: forward, 5′-GAAGTTCGCCTTGATGC-
CGTTCTTCTG; reverse, 5′-TCCAGTTCTGCATTCCTGTACG. 
Thy1.2-Flag-MFN2R94Q line 44 heterozygous mice, Thy1.2-Flag-MF-
N2WT mice, and PrP-Flag-MFN1 mice were generated in house and 
deposited in The Jackson Laboratory (JAX stock 29745, JAX stock 
032728, and JAX stock 033391, respectively).
PrP-Flag-MFN1 mice. Human MFN1 cDNA cloned into pBlue-
scriptR plasmid was obtained from Open Biosystems (MHS1010-
9203753). An AgeI-Kosak-ATG-FLAG sequence was inserted after 
the 5′ UTR, and an XhoI site was inserted before the 3′ UTR of 
human MFN1 cDNA using QuikChange. Flag-MFN1 was then cut out 
from the pBluescriptR plasmid with AgeI and XhoI restriction sites 
and subcloned into the PrP promoter construct. The final PrP-Flag-
MFN1 plasmid was linearized with NotI restriction enzyme diges-
tion. The linearized plasmid was used for pronuclear injection to 
create transgenic mice on the C57BL/6J background. Genotyping of 
founder mice was done using PCR. Primers were as follows: forward, 
5′-CAATTCTAGTTTTCTCTTTTTGTTGTTTTAAAGGACTCC; 
reverse, 5′- GGGAGAACTTTATCCCACAACA.
MFN2R94Q: MFN1 and MFN2R94Q: MNF2WTdouble-transgenic mice. 
MFN2R94Q mice were crossed with either MFN1 mice or MFN2WT mice 
to generate MFN2R94Q: MFN1 or MFN2R94Q: MFN2WT heterozygous 
double-transgenic mice. To fluorescently label mitochondria in vivo, 
MFN2R94Q mice or MFN2R94Q: MFN1 mice were crossed with Thy1-CFP/
COX8A mice from The Jackson Laboratory to make MFN2R94Q: CFP/
COX8A mice or MFN2R94Q: MFN1: CFP/COX8A mice.
Mouse behavioral analysis
Rotarod test. The rotarod was used to measure motor function and 
coordination. Mice were placed on a rod elevated 18 inches above a 
soft surface. For each rotarod session, the rod was set at a constant 
speed of 5 rpm with a cut-off time at 4 minutes. Each session consisted 
of 3 trials with a 30-minute intertrial period in which mice were placed 
back in their home cages. The latency for the mice to fall off the rod 
was averaged across the 3 trials.
Grip-strength test. This test measures grip-force ability of the 
forelimbs and hind limbs. For measuring tensile force, the mouse 
was held by the base of the tail and allowed to grip a metal grid 
either with its forepaws alone or with both forepaws and hind paws. 
The mouse was then gently pulled horizontally to exert the tensile 
force. The peak force (in g) at the point the mouse released its grip 
was recorded through a digital force gauge attached to the metal 
grid. Three successive measurements were averaged for both the 
forelimbs and the 4-paws grip strengths.
Open-field test. Spontaneous motor activity of the mice was mea-
sured in the open-field test. Mice were individually placed into a clear 
Plexiglas chamber (16 inches long × 16 inches wide × 15 inches high) 
surrounded by 2 bands of photobeams and optical sensors that mea-
levels of MFN1 in the nervous system is a viable therapeutic 
approach for CMT2A, as Thy1.2-MFN2R94Q:Prp-MFN1 double- 
transgenic animals showed near complete rescue of ocular, neu-
romuscular, and histologic phenotypes seen in Thy1.2-MFN2R94Q 
mice. While Mfn1- or Mfn2-null mice are embryonic lethal due to 
placental defects (1), conditional removal of Mfn2, but not Mfn1, 
postnatally led specifically to neurodegeneration (10, 23, 24), likely 
due to the fact that Mfn1 levels are very low in the nervous system 
(27). MFN1 and MFN2 are 80% identical (22) and are capable of 
heterodimer formation (1), and MFN1 expression can rescue mito-
chondrial fusion and transport defects caused by the loss of MFN2 
in MEFs and DRG neurons (26, 27), but not other functions, such 
as altered ER-mitochondrial interactions (2). Therefore, these data 
support the concepts that (a) the origin of nervous system–specific 
defects in CMT2A is due to the relative lack of MFN1 expression and 
(b) functions that are MFN2 specific are not critical for the toxicity 
of MFN2 mutants in CMT2A, as they would presumably not be res-
cued by restoring MFN1:MFN2 balance.
We also observed that increasing MFN2 levels in neurons (in 
SH-SY5Y cells or by generating double-transgenic MFN2R94Q:MFN2WT 
mice) could similarly rescue the dominant negative effect of mutant 
MFN2R94Q. This further supports the idea that the relative number of 
functional MFN molecules (either MFN1 or MFN2) in a tissue is the 
key driver of toxicity of mutant MFN2R94Q and that increasing either 
MFN1 or MFN2 could be used therapeutically in CMT2A. However, 
for approaches increasing endogenous gene expression, augmenting 
MFN1 would be preferable, as it would effectively change the ratio 
of functional MFN molecules, while augmenting MFN2 expression 
would have no effect on this ratio or could worsen the phenotype.
It is unknown why MFN1 levels are very low in the adult nervous 
system, but the fact that Prp-MFN1 transgenic mice are phenotypi-
cally normal indicates that MFN1 overexpression at levels equivalent 
to MFN2 is well tolerated. Likewise, increased levels of MFN2 in the 
Thy1.2-MFN2WT mice were also well tolerated and could similarly rescue 
the toxic effects of mutant MFN2 expression. This raises the possi-
bility that augmenting MFN1 or MFN2 expression in the nervous 
system may have broader therapeutic applications beyond CMT2A. 
Impaired mitochondrial dynamics, including fusion, fission, and 
transport, have been implicated in other forms of CMT (59–62) 
and many other neurodegenerative diseases, including Parkinson’s 
disease, Huntington’s disease, amyotrophic lateral sclerosis, and 
Alzheimer’s disease (7, 8, 63). Indeed, a recent report indicated that 
increasing MFN2 levels in neurons was protective in a model of amy-
otrophic lateral sclerosis, suggesting that MFN2WT mice may be intrin-
sically more resistant to neurodegeneration (64). Although upstream 
mechanisms vary across these neurodegenerative diseases, aug-
menting MFN1 or MFN2 could mitigate mitochondrial dysfunction 
that occurs as a shared pathophysiology in neurodegeneration.
Methods
Generation of transgenic mice
Thy1.2-Flag-MFN2WT or Thy1.2-Flag-MFN2R94Q mice. An XhoI site 
was inserted using QuikChange (Agilent) to remove MFN2 3′ 
UTR in the pEGFP-HA- MFN2WT and pEGFP-HA-MFN2R94Q cDNA 
constructs (32). The HA tag was then replaced with the Flag tag 
using In-Fusion cloning (Clontech). The resulting Flag-MFN2WT 
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Immunohistochemistry analysis of retinal whole mount and retinal 
sections. Retinal whole mount was prepared according to published 
protocols (67). Briefly, eyeballs were fixed in 4% PFA for 1 hour and 
transferred to PBS (pH 7.35–7.45) for dissecting. Under the dissecting 
microscope, the cornea and lens were removed and 4 equal cuts were 
made to flatten the eyeball. Neural retina was dissected out, trans-
ferred to filter paper, and fixed for 1 hour in the same fixative. The 
neural retina was washed with PBS, infiltrated with gradient sucrose 
(10%, 20%, and 30%), and left in 30% sucrose overnight at 4°C. On 
the next day, the retina was frozen and thawed 3 times in an Eppen-
dorf tube with 30% sucrose on dry ice. The retina was washed with 
PBS and processed for immunofluorescence staining. Retinal sec-
tions were prepared according to published protocols (67). Briefly, 
eyes were removed and immersed in 2% PFA for 1 hour. Eyes were 
then infiltrated with sucrose and embedded in OCT. Horizontal fro-
zen sections (12 μm) were cut on a cryostat. The primary antibodies 
used were anti-neurofilament (RT97, 1:1,000, catalog CBL212, Milli-
poreSigma) and anti-Brn3a (1:200, catalog sc-31984, Santa Cruz Bio-
technology Inc.) for RGCs.
Retinas were examined, and images were taken using the Leica 
DM6000B microscope (Leica Microsystems). The numbers of RGC 
cells (Brn3a positive) in the retinal whole mount were quantified. Four 
images in the center and in the periphery were taken, respectively, per 
animal. Four or five animals were used per genotype. The quantifica-
tion was performed using ImageJ software with the threshold and the 
analyze particles functions.
NMJ staining. Quadriceps muscle was dissected from mice and 
post-fixed with 4% PFA on ice for 1 hour. After PBS wash, muscle was 
embedded with 4% low melting agarose. Serial sections (70 μm thick) 
were cut. Agarose sections were placed in a 24-well plate, blocked with 
5% normal donkey serum (diluted in PBS) for 30 minutes, and stained 
with 0.5 μg/ml α-bungarotoxin (catalog B-13423, Thermo Fisher Sci-
entific) for 1 hour. The stained sections were mounted on slides with 
ProLong Gold Antifade Mountant. Z-stack images were taken using a 
Nikon Eclipse Ti microscope.
Fluoro-Jade staining of degenerating axons. Sets of paraffin sec-
tions (4 μm) were deparaffinized using xylene and then hydrated with 
decreasing concentrations of ethanol. The slides were immersed in 
the following solutions in sequence: PBS, 5 minutes; 1%NaOH in 80% 
ethanol, 5 minutes; 70% ethanol, 2 minutes; H2O, 2 minutes; 0.06% 
KMnO4 in H2O, 17 minutes; H2O, 2 minutes; 0.001% Fluoro-Jade C 
(catalog AG235, MilliporeSigma) in 0.1% acetic acid with DAPI, 30 min-
utes; and H2O, 3 times, 2 minutes per time. Then slides were dried by 
draining excess water and placed on a slide warmer at 50°C for 10 min-
utes. Finally, slides were coverslipped using DPX mounting medium. 
Images were taken using an Olympus BX51 Upright Microscope. 
Fluoro- Jade signals were quantified with ImageJ software. After back-
ground subtraction, Fluoro-Jade–positive signals per ROI were quanti-
fied and presented as pixle2/mm2 ROI.
Toluidine blue staining of spinal cord and tibial nerve plastic sections. 
A 1 ml long segment of spinal cord (between thoracic and lumbar 
region) or distal tibial nerve were harvested for processing of epoxy 
resin blocks. The specimens were fixed in 3% glutaraldehyde in 0.1M 
phosphate buffer, osmicated in 2% osmium tetroxide in 0.1M phos-
phate buffer, dehydrated in increasing graded solutions of ethanol 
and acetone, and finally embedded in epoxy resin. Sections (0.5 μm) 
were cut and stained with toluidine blue. Axon counts and axon area 
sured horizontal locomotor and vertical rearing activity. Animals 
moved freely within the enclosure for 60 minutes. Movement was 
detected as breaks within the photobeam matrices and automatically 
recorded using PAS software (San Diego Instruments).
Visual acuity test. Visual acuity measured by OKR was conducted 
on both mutated and control mice. The test was done in an observer- 
blinded fashion as reported previously (66).
Western blot analysis. Mouse brain or spinal cord tissue was lysed 
with RIPA buffer and quantified using BCA protein assay (Pierce). 
Protein samples were separated on 10% precast polyacrylamide gels 
and transferred to nitrocellulose blots. Primary antibodies for Western 
blot included anti-Flag (MilliporeSigma, catalog F3165), anti-MFN2 
(Abcam, catalog ab56889), anti-MFN1 (Proteintech, catalog 13798-1-
AP), and anti-GAPDH (MilliporeSigma, catalog G8795). Signals were 
detected using fluorescent secondary antibodies and the Odyssey 
imager from LI-COR.
Immunohistochemistry analysis of brain, spinal cord, and optic 
nerve. Tissue were fixed in 4% paraformaldehyde (PFA) (pH 7.4) for 
5 days for brain and spinal cord and for 2 days for optic nerve. After 
fixation, tissues were embedded in paraffin and 4 μm thick serial 
sections were cut, including coronal sections for brain, cross sec-
tions for spinal cord, and both cross and longitudinal sections for 
optic nerve. Sets of sections were deparaffinized using xylene and 
then hydrated with decreasing concentrations of ethanol. After dep-
araffinization, antigen retrieval was performed by submerging the 
sections in citrate buffer (pH 6.0) and microwaving at 800W for 
10 minutes. For SMI32 staining, the microwave step was followed 
by 5 minutes incubation in 90% formic acid. For immunostaining, 
the sections were treated with 1% H2O2/methanol and blocked with 
10% horse serum, followed by overnight incubation with primary 
antibodies. The next day, sections were incubated with fluorescent 
secondary antibodies for 4 hours at room temperature. Nuclei were 
stained with DAPI and mounted with ProLong Gold Antifade Moun-
tant (Thermo Fisher Scientific). Positive and negative controls were 
run along each batch of sections processed.
Primary antibodies were as follows: anti-FLAG (1:500, catalog 
F3165, Sigma-Aldrich), anti-COXIV (1:200, catalog ab16056, Abcam 
Inc.), anti-p62 (1:500, catalog BML-PW9860-0100, Enzo Life Sci-
ences), anti-ubiquitin (1:500, catalog MAB1510, MilliporeSigma), 
anti-neurofilament H nonphosphorylated (SMI 32, 1:500, catalog 
801701, Biolegend), anti-NeuN (1:200, catalog MAB377, MilliporeSig-
ma), anti-GFAP (1:500, catalog Z0334, Dako-Agilent Technologies 
Inc.), anti-Iba1 (1:250, catalog 019-19741, Wako). Secondary antibod-
ies were as follows: 1:1000, Alexa Fluor 488 (Molecular Probes, cata-
log A11034, catalog A11029) and Alexa Fluor 594 (Molecular Probes, 
catalog A11037, catalog A11032).
Stained sections were evaluated and imaged with an Olympus 
BX51 Upright Microscope. The quantification of fluorescent signals 
was performed using ImageJ software (NIH) with the threshold and 
the analyze particles functions. For optic nerve, the number of neu-
rofilament spheroids (size more than 50 pixel2) was quantified. For 
neuron counts, the numbers of NeuN-positive cells were counted in 
brain and spinal cord. For astrogliosis analysis, GFAP-positive signals 
were quantified as percentage of area. For microgliosis analysis, num-
bers of Iba1-positive cells were counted. To analyze mitochondrial 
clusters, numbers of p62-positive mitochondrial clusters per region 
of interest (ROI) (0.01 mm2) in the hippocampus were quantified.
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figure legends. Data are presented as mean ± SEM (n ≥ 3). Differences 
are considered statistically significant at P < 0.05. Unpaired 2-tailed Stu-
dent’s t test was used for 2-group comparisons, unless it is stated that 
a 1-tailed t test was used. Either 1- or 2-way ANOVA with Tukey’s test 
was used for multiple comparisons. The log-rank test with Bonferroni’s 
correction was used for survival curve comparison. The Kolmogorov- 
Smirnov test was used to compare frequency distribution.
Study approval. All animal experiments were performed after prior 
approval by the IACUC at Cedars-Sinai Medical Center and conformed 
to the policies and procedures of the Comparative Medicine Depart-
ment, Cedars-Sinai Medical Center, as well as the NIH Guide for the 
Care and Use of Laboratory Animals (National Academies Press, 2011).
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measurements were quantified as previously described in detail (68). 
Briefly, with ImageJ software, the threshold function was used to high-
light axoplasm only on whole nerve sections; the analyze particle func-
tion was then used to count the number of myelinated axons and their 
cross-sectional areas in each nerve.
Imaging analysis of mitochondria and mitophagy in cultured cells. 
Mitochondrial labeling and mitophagy assay were performed as 
previously described (43). Briefly, MEFs were grown on coverslips. 
WT MEFs were infected with lentivirus expressing HA-MFN2WT or 
HA-MFN2R94Q (32). Mitochondria in MEFs were labeled with Mio-
toTracker Green (200 nM, Invitrogen, catalog M7514) and tetrameth-
ylrhodamine, ethyl ester (TMRE; 200nM, Invitrogen, catalog T-669). 
For mitophagy studies, MEFs were stained with MitoTracker Green 
and transfected with an mCherry-Parkin–expressing adenovirus vec-
tor or stained with LysoTracker Deep Red (50 nM, Invitrogen, cata-
log L-7528); carbonyl cyanide-4-phenylhydrazone (FCCP) (10 μM, 
1 hour) was applied as a positive control. Images were taken using a 
Nikon Ti confocal microscope with a ×60 1.3 NA oil-immersion objec-
tive. Imaging analysis was performed as previously described (43).
For in vitro rescue assay, Mfn1/Mfn2-null MEFs (ATCC, CRL-2994) 
or Mfn2-null MEFs (ATCC, CRL-2993) were treated with allosteric MFN2 
modulating peptide (TAT-MP1Gly), and mitochondria were labeled with 
MitoTracker Green. SH-SY5Y cells (ATCC, CRL-2266™) were infected 
with lentivirus (HA-MFN2 R94Q in CCImCh) expressing HA-MFN2R94Q 
with IRES-mitoCherry alone or in combination with TAT-MP1Gly treat-
ment or lentivirus expressing Mfn1. After 96 hours, cells were fixed with 
4% PFA and kept in PBS. Images were taken using a Nikon Eclipse Ti 
microscope. Image analysis was performed using ImageJ software to 
count the number of cell aggregates. Peptide TAT-MP1Gly was obtained 
in house and synthesized as previously reported (40).
RNA-Seq and pathway analysis. RNA was purified from spinal cord 
lumbar segment using TRIzol and the Purelink RNA Mini Kit (Thermo 
Fisher Scientific, 12183018A). RNA-Seq library was prepared using 
TruSeq Stranded mRNA Library Preparation Kit (Illumine, RS-122-
2102). Single-end 75 bp sequencing was performed with an Illumina 
NextSeq 500 at the Cedars-Sinai Genomics Core Facility. The FASTQ 
files were uploaded to Illumina BaseSpace for alignment to the mouse 
genome build mm10 using TOPHAT. The resulting BAM files were 
imported to Partek software to generate RPKM values and for differ-
ential expression analysis. The RPKM values were uploaded to Gene 
Cluster 3.0 for PCA. The genes that fell into PC1 were uploaded to 
GSEA for pathway analysis (69).
Accession code. All original raw and processed RNA-Seq data were 
deposited in the NCBI’s Gene Expression Omnibus database (GEO 
GSE116863).
Statistics. All statistical analysis was performed using GraphPad 
Prism software (version 6.0). Statistical methods are indicated in the 
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